A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
OVARD
Multicentre, Non-interventional, Observational, Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD+ Ovarian Cancer Patients in Russian Federation
1 other identifier
observational
414
1 country
24
Brief Summary
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history. It is estimated that approximately 400 patients will be enrolled in approximately 25 sites. Demographic and clinical characteristics, treatment approaches and outcomes in HRD+ patients with high-grade epithelial ovarian, primary peritoneal, and/or fallopian tube cancer will be collected at baseline and on prospective visits.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2023
CompletedStudy Start
First participant enrolled
June 21, 2023
CompletedFirst Posted
Study publicly available on registry
June 26, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 29, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 29, 2025
CompletedMay 28, 2026
May 1, 2026
1.9 years
June 15, 2023
May 25, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
To describe the demographic and clinical characteristics of the patient population with HRD-positive OC (HRD+ BRCAwt and HRD+ BRCAm)
Demographic and baseline clinical characteristics will be summarized descriptively for the entire cohort of eligible patients.
18 months
Secondary Outcomes (2)
To describe diagnostic and primary treatment approaches (surgery, first line chemotherapy+/-bevacizumab) of HRD+ with high-grade, epithelial ovarian, primary peritoneal, and/or fallopian tube cancer in routine practice
18 months
To describe first-line maintenance treatment approaches
18 months
Eligibility Criteria
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history. It is estimated that approximately 400 patients will be enrolled in approximately 25 sites. Demographic and clinical characteristics, treatment approaches and outcomes in HRD+ patients with high-grade epithelial ovarian, primary peritoneal, and/or fallopian tube cancer will be collected at baseline and on prospective visits.
You may qualify if:
- Patients ≥18 years of age;
- Willing and ability to provide written informed consent for participation in the study;
- Known status HRD+ (positive BRCAm test and/or positive Genomic Instability test);
- Patients with histologically confirmed diagnosis of high-grade IC-IV FIGO stages epithelial ovarian, primary peritoneal, and/or fallopian tube cancer;
- Completed primary treatment (surgery and/or 1st line CT +/- bevacizumab) no more than 3 months after completion of primary treatment.
You may not qualify if:
- Patients participating in other clinical studies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (24)
Research Site
Arkhangelsk, Russia
Research Site
Barnaul, Russia
Research Site
Chelyabinsk, Russia
Research Site
Grozny, Russia
Research Site
Irkutsk, Russia
Research Site
Izhevsk, Russia
Research Site
Kaliningrad, Russia
Research Site
Kaluga, Russia
Research Site
Krasnodar, Russia
Research Site
Krasnoyarsk, Russia
Research Site
Lyubertcy, Russia
Research Site
Moscow, Russia
Research Site
N.Novgorod, Russia
Research Site
Nal'chik, Russia
Research Site
Novosibirsk, Russia
Research Site
Omsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saratov, Russia
Research Site
Sochi, Russia
Research Site
Tomsk, Russia
Research Site
Ufa, Russia
Research Site
Vladivostok, Russia
Research Site
Yakutiya, Russia
Research Site
Yaroslavl, Russia
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 15, 2023
First Posted
June 26, 2023
Study Start
June 21, 2023
Primary Completion
May 29, 2025
Study Completion
May 29, 2025
Last Updated
May 28, 2026
Record last verified: 2026-05